Nexchain Opens Limited-Time $0.05 Bonus Window Before Major Project Update
[PRESS RELEASE – New York, USA, June 17th, 2026]
Nexchain has opened a limited-time $0.05 bonus entry window ahead of a major project update scheduled for next week. The AI-powered Layer 1 blockchain is preparing to share upcoming milestones and launch progress, while the current bonus pricing remains available for a short period before the project moves into its next phase.
The Six-Day Hold Creates A Clear Entry Point
Nexchain has linked its stages to protocol development and wider network availability. The next project update is expected next week, adding timing to the current pricing structure. This keeps the focus on stage progress, product work, and upcoming access changes.
A Quiet Build Now Moves Toward Public Update
The current stage therefore carries both timing and product context. The network presents itself as an AI-built Layer 1 blockchain with decentralized security and automation. Its design combines Proof-of-Stake with AI-driven algorithms through a hybrid consensus model.
Nexchain lists 400,000 transactions per second through AI optimization and parallel processing. It also lists transaction fees at $0.001 for transfers and smart contract activity.
How NEX Powers The Nexchain Ecosystem
The NEX token carries planned utility across transaction fees, staking, governance, and AI service payments. NEX can support smart contract interactions, decentralized app payments, validator incentives, and AI model services. Additionally, Nexchain AI lists use cases across finance, healthcare, supply chains, IoT, content, AI services, and administration. These use cases show how NEX fits into the planned ecosystem.
The tokenomics structure lists 2.15 billion NEX as the total initial supply. Public allocation stands at 20%, treasury at 17%, and ecosystem support at 15%. Team allocation stands at 10%, liquidity at 8%, private allocation at 7%, and rewards at 7%. Burn allocation stands at 6%, while seed and marketing each hold 5%.
The coming update will add the next project detail before the phase changes. Market participants can review the terms, compare the current price levels, and assess the next update before the $0.05 entry period ends.
About Nexchain
Nexchain is an AI-powered Layer 1 blockchain built to combine artificial intelligence with scalable blockchain infrastructure. The project focuses on high transaction throughput, AI-driven network optimization, EVM compatibility, and tools designed to support next-generation decentralized applications. With testnet development progressing and audited smart contracts already completed, the team is now entering a more public phase of its launch preparation.
For More Details, users can visit:
Website: https://nexchain.ai/
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
